Emapalumab, an IFN-γ-targeted monoclonal antibody, has been approved for pHLH in patients with refractory, recurrent, or progressive disease, or those intolerant to conventional therapy - including intolerance due to severe pancytopenia. This evidence concerns the gene IFNG and Pancytopenia.